Peer-reviewed veterinary case report
Radioactive iodine treatment for thyroid cancer in dogs response
By Jegatheeson, Selvi et al.·Published in Veterinary and comparative oncology·2022·Melbourne Veterinary School, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Response of canine thyroid carcinomas to radioiodine.
- Species:
- dog
Plain-English summary
A group of dogs with thyroid cancer received treatment with radioactive iodine to see how well it worked. Out of 66 dogs treated, about 35% showed a positive response, with some dogs experiencing complete or partial shrinkage of their tumors. Most dogs (76%) showed improvement in their symptoms, such as increased energy or reduced swelling. The average time before the cancer progressed was about 10 months, and the overall survival time was around 18 months. This treatment can help many dogs feel better and live longer after a diagnosis of thyroid cancer.
People also search for: dog thyroid cancer treatment · radioactive iodine for dogs · dog cancer survival rates
Abstract
Radioactive iodine (I) has previously been reported to prolong survival in dogs with thyroid carcinoma. This study aimed to describe tumour response and progression-free interval (PFI) in dogs with thyroid carcinomas treated withI. Secondary aims were to describe overall survival time (OST) and prognostic factors. A bi-institutional retrospective review of records identified 66 dogs with thyroid carcinoma treated withI from January 2010 to April 2020. Response was described using RECIST or a subjective response assessment where specific tumour measurements were not available. Forty-eight dogs (72.7%) were treatment naïve and 18 dogs (27.3%) had received prior therapy at the time ofI treatment. Objective responses were available for 34 dogs and subjective responses for 58 dogs. The overall response rate was 35.3% (four complete and eight partial responses). Improvement of clinical signs was seen in 76.2% of dogs (32/42). Kaplan-Meier-estimated median PFI (95% confidence interval [CI]) was 301 (217-578) days and OST (95% CI) was 564 (421-865) days. Prior therapy was associated with a lower hazard for progression (hazard ratio [HR] 0.260 95% CI 0.123-0.548, p = .0004). Treatment of thyroid carcinoma usingI can effectively alleviate clinical signs and reduce disease burden in a proportion of dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34476889/